Are we doing enough to help people make the best treatment and prevention decisions?

 12 avril 2016 •  Par Bob Leahy

In an era where sometimes difficult, science-based decisions are routinely required of both positive and negative individuals− think when to start treatment, or the relative benefits of PrEP vs condoms− are we doing enough to steer people away from bad decisions? First we need to acknowledge that even in a non-judgmental environment such as ours, some decisions just aren’t wise. Charlie Sheen and the allure of the goat’s milk cure proved that quite publicly. So did this Facebook commenter opining recently when to start treatment: “It’s best to wait until there is a patch, a spray or a cure.” In...

Pour en savoir plus...
 

Supervised injection in Toronto will improve the health of people who inject drugs

 5 avril 2016 •  Par Drs. Ahmed Bayoumi and Carol Strike

Over the past year, advocates or elected officials in Montreal, Ottawa, Victoria, Baltimore, New York City, Ithaca (NY), Seattle, San Francisco, Glasgow and four cities in Ireland have called  for the implementation of supervised injection services. More recently, Toronto’s Medical Officer of Health Dr. David McKeown recommended that the Board of Health start a community consultation process toward establishing supervised injection services within three existing facilities in the city. The Board voted unanimously in favour.  As the lead investigators of the TOSCA study  (the Toronto and Ottawa Supervised Consumption Assessment), we support Dr. McKeown’s proposal and look forward to the...

Pour en savoir plus...
 

We’re all mad here: It’s time to demand affordable Hep C treatment!

 22 mars 2016 •  Par Patricia Bacon

My daughter has a smartphone cover that says: “We’re all mad here”. It’s from Alice in Wonderland. I like it; and when it comes to hepatitis C treatment and pricing, it’s quite on point. In 2014, Canada and the rest of the world turned a miraculous corner – a cure for viral hepatitis C was on the market. Wonderful and amazing. Why? Well, viral hepatitis C is the only chronic viral infection that now has a cure – that is, a cure for virtually everyone, with a cure rate of 95 per cent.

Pour en savoir plus...
 

5 ways that PrEP highlights gender inequities in HIV

 8 mars 2016 •  Par San Patten

One of the most memorable moments in my 20 years working in the HIV field happened in a standing-room-only meeting hall in Vienna at the International AIDS Conference in 2010. This was the moment that the clinical trial CAPRISA 004 announced proof-of-concept for prevention of HIV among women using a vaginal microbicide (1% tenofivir gel). The entire room broke out in a standing ovation and tears of joy. Finally! A prevention tool that could allow a woman to protect herself in sexual encounters, regardless of the desires and wishes of her sexual partner. Five years later, microbicides have not yet...

Pour en savoir plus...
 

La déclaration de Santé Canada sur le statut de la naloxone est un changement judicieux dans le paradigme des politiques sur les drogues

 4 mars 2016 •  Par Dre Lynne Leonard 

The administration of naloxone, a chemical compound that effectively temporarily reverses the effects of an opioid overdose, is recommended by the World Health Organization to be used in the case of an opioid overdose. Naloxone is currently available in Canada only in an injectable form and by prescription only; it can only be administered to the person named on the prescription, not to a third party.

Pour en savoir plus...
 

Queer women are ignored in HIV research: this is a problem and here is why it matters

 23 février 2016 •  Par Carmen Logie

Lesbian, bisexual and queer women are rarely included in HIV research. Women who have sex with women, and their HIV infection rates, are not captured anywhere because women cannot report having a woman as a sexual partner in Canada’s HIV statistics. The current record only allows women to report HIV exposure either through injection drug use or heterosexual sex. This contributes to the erasure of women’s sexual and gender diversity and fluidity in HIV research. Queer* women are ignored in HIV research: this is a problem and here is why it matters.

Pour en savoir plus...